The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
 
Shiao-Pei S. Weathers
No Relationships to Disclose
 
Stan Xiaosi Han
No Relationships to Disclose
 
Diane D Liu
No Relationships to Disclose
 
Charles A. Conrad
No Relationships to Disclose
 
Mark R. Gilbert
Honoraria - Abbvie; Cell Medica; Genentech/Roche; HERON; Merck; Wellcome Trust
Consulting or Advisory Role - Abbvie; Cell Medica; Genentech/Roche; HERON; Merck/Schering Plough; Wellcome Trust
Research Funding - Genentech/Roche; GlaxoSmithKline; Merck/Schering Plough
Travel, Accommodations, Expenses - Abbvie; Genentech/Roche; Merck/Schering Plough
 
Monica Elena Loghin
No Relationships to Disclose
 
Barbara Jane O'Brien
No Relationships to Disclose
 
Marta Penas-Prado
Research Funding - Bayer (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
 
Vinay K. Puduvalli
Honoraria - Celgene; Foundation Medicine; Novartis; Threshold Pharmaceuticals
Consulting or Advisory Role - Celgene; Foundation Medicine; Novartis; Threshold Pharmaceuticals
Research Funding - DNAtrix; Genentech; Novartis
 
Ivo Tremont-Lukats
No Relationships to Disclose
 
W. K. Alfred Yung
Honoraria - Actelion; Merck
Consulting or Advisory Role - Actelion; Merck
Travel, Accommodations, Expenses - Actelion
 
John Frederick De Groot
Honoraria - Mundipharma
Consulting or Advisory Role - Celldex; Deciphera; Foundation Medicine; Genentech; Novartis; VBL Therapeutics
Research Funding - AstraZeneca; Deciphera; EMD Serono; Lilly; Novartis; Sanofi